{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:55Z","timestamp":1791232435074,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/bjc.2014.233","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T20:00:31Z","timestamp":1399406431000},"page":"2647-2654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies"],"prefix":"10.1038","volume":"110","author":[{"given":"A R","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M N","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S F","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M P","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K T","family":"Levinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A B","family":"Suttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H A","family":"Burris III","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,6]]},"reference":[{"key":"BFbjc2014233_CR1","unstructured":"Abad M, Calvo I, Martinez N, Herreo M, Quijano Y, Duran H, Aranda M, Suarez A, Lopez-Rios F, Perez D, Perea S, Hidalgo M, Garcia-Estevez L (2012) Neoadjuvant bevacizumab and trastuzumab in combination with weekly paclitaxel as neoadjuvant treatment in HER2-positive breast cancer: results from a phase II trial (AVANTHER). J Clin Oncol 30 (15S): Abstract 602."},{"issue":"2","key":"BFbjc2014233_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10549-012-2369-x","volume":"137","author":"M Cristofanilli","year":"2013","unstructured":"Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME (2013) A randomized phase II study of lapatinib+pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat 137 (2): 471\u2013482.","journal-title":"Breast Cancer Res Treat"},{"issue":"18S","key":"BFbjc2014233_CR3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/jco.2007.25.18_suppl.1027","volume":"25","author":"JP Crown","year":"2007","unstructured":"Crown JP, Burris HA III, Jones S, Koch KM, Fittipaldo A, Parikh R, Koehler M (2007) Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). J Clin Oncol 25 (18S): Abstract 1027.","journal-title":"J Clin Oncol"},{"issue":"3","key":"BFbjc2014233_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10637-012-9885-8","volume":"31","author":"MJ de Jonge","year":"2013","unstructured":"de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI (2013) Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs 31 (3): 751\u2013759.","journal-title":"Invest New Drugs"},{"issue":"26","key":"BFbjc2014233_CR5","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (26): 2733\u20132743.","journal-title":"N Engl J Med"},{"issue":"15","key":"BFbjc2014233_CR6","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1021\/jm800566m","volume":"51","author":"PA Harris","year":"2008","unstructured":"Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA (2008) Discovery of 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl)amino)-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51 (15): 4632\u20134640.","journal-title":"J Med Chem"},{"issue":"33","key":"BFbjc2014233_CR7","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27 (33): 5538\u20135546.","journal-title":"J Clin Oncol"},{"issue":"3","key":"BFbjc2014233_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10549-012-2399-4","volume":"137","author":"SR Johnston","year":"2013","unstructured":"Johnston SR, G\u00f3mez H, Stemmer SM, Richie M, Durante M, Pandite L, Goodman V, Slamon D (2013) A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 137 (3): 755\u2013766.","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"BFbjc2014233_CR9","first-page":"1069","volume":"88","author":"SF Jones","year":"2004","unstructured":"Jones SF, Burris HA, Yardley DA, Greco FA, Spigel DR, Raefsky EL, Hainsworth JD, Willcutt NT, Calvert SA, Versola MJ (2004) Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel. Breast Cancer Res Treat 88 (suppl 1): Abstract 1069.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"BFbjc2014233_CR10","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1158\/1078-0432.CCR-0951-3","volume":"10","author":"GE Konecny","year":"2004","unstructured":"Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD (2004) Association between HER-2\/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10 (5): 1706\u20131716.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"BFbjc2014233_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","volume":"66","author":"GE Konecny","year":"2006","unstructured":"Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 (3): 1630\u20131639.","journal-title":"Cancer Res"},{"issue":"9","key":"BFbjc2014233_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/00001813-200410000-00007","volume":"15","author":"D Lau","year":"2004","unstructured":"Lau D, Guo L, Gandara D, Young LJ, Xue L (2004) Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs 15 (9): 871\u2013875.","journal-title":"Anticancer Drugs"},{"issue":"48","key":"BFbjc2014233_CR13","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1038\/onc.2009.277","volume":"28","author":"KA Olaussen","year":"2009","unstructured":"Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, Raza SQ, Richon C, Dessen P, Lazar V, Soria JC, Kroemer G (2009) Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene 28 (48): 4249\u20134260.","journal-title":"Oncogene"},{"issue":"10","key":"BFbjc2014233_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/labinvest.3700466","volume":"86","author":"BP Rubin","year":"2006","unstructured":"Rubin BP, Duensing A (2006) Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 86 (10): 981\u2013986.","journal-title":"Lab Invest"},{"issue":"24","key":"BFbjc2014233_CR15","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (24): 2542\u20132550.","journal-title":"N Engl J Med"},{"issue":"3","key":"BFbjc2014233_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","volume":"14","author":"Y Shaked","year":"2008","unstructured":"Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14 (3): 263\u2013273.","journal-title":"Cancer Cell"},{"issue":"6","key":"BFbjc2014233_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarb\u00e1 JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28 (6): 1061\u20131068.","journal-title":"J Clin Oncol"},{"issue":"12","key":"BFbjc2014233_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1634\/theoncologist.2010-0095","volume":"15","author":"AR Tan","year":"2010","unstructured":"Tan AR, Dowlati A, Jones SF, Infante JR, Nishioka J, Fang L, Hodge JP, Gainer SD, Arumugham T, Suttle AB, Dar MM, Lager JJ, Burris HA (2010) Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 15 (12): 1253\u20131261.","journal-title":"Oncologist"},{"issue":"3","key":"BFbjc2014233_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3): 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"issue":"9829","key":"BFbjc2014233_CR20","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 (9829): 1879\u20131886.","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014233","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:23:12Z","timestamp":1684416192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFbjc2014233"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.233","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"22 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ART has received research funding from GlaxoSmithKline. JRI reports a consultant\/advisory role (uncompensated). ABS is a GlaxoSmithKline employee and stockholder. AD, MNS, SFJ, JB, MPK, KTL, and HABIII report no potential conflict of interest associated with this publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}